nach oben

International Journal of Colorectal Disease

Erschienen in:

Open Access 01.12.2024 | RESEARCH

Analysis of the differential expression of serum miR-21-5p, miR-135-5p, and miR-155-5p by Bifidobacterium triplex viable capsules during the perioperative stage of colorectal cancer

verfasst von: Jing Zhang, Ji Guo, Ruochong He, Ji Li, Bingyi Du, Yi Zhang, Rongliang He, Haixia Cheng

Erschienen in: International Journal of Colorectal Disease | Ausgabe 1/2024

Abstract

Objective

In this study, we investigated the impact of perioperative administration of Bifidobacterium triplex viable capsules on the serum levels of circulating miR-21-5p, miR-135-5p, and miR-155-5p in patients with colorectal cancer (CRC). The purpose of this study is to provide a foundation for future research on the use of Bifidobacterium triplex viable capsules to enhance postoperative recovery in patients with CRC.

Methods

A total of 60 patients with primary CRC admitted to the Department of General Surgery at Shanxi Bethune Hospital between June 2020 and December 2020 were selected and randomly divided into two groups: 20 cases in the control group and 40 cases in the experimental group. The experimental group was administered oral Bifidobacterium triplex viable capsules during the perioperative period, while the control group was administered oral placebo. Before and after the perioperative period, the expression levels of miR-21-5p, miR-135-5p, and miR-155-5p were compared in the serum of both groups of patients. Furthermore, we established the prognostic value of these three miRNAs in CRC patients.

Results

After surgery, the expression levels of miR-21-5p, miR-135-5p, and miR-155-5p decreased in both groups of patients (P < 0.05). Significantly greater differences were observed between miR-21-5p and miR-135-5p (P < 0.001). Expression levels of serum miR-21-5p (P = 0.020) and miR-135-5p (P = 0.023) decreased significantly more in the experimental group than in the control group. The levels of the above three miRNAs after surgery did not correlate with 3-year OS (HR = 4.21; 95% CI 0.37–47.48; log-rank P = 0.20) or 3-year DFS (HR = 1.57; 95% CI 0.32–7.66; log-rank P = 0.55) in two groups.

Conclusion

Radical surgery reduces the levels of serum miR-21-5p, miR-135-5p, and miR-155-5p expression in patients with CRC. The use of Bifidobacterium triplex viable capsules assists in achieving quicker perioperative recovery from radical surgery in CRC patients, and this underlying mechanism may be associated with the regulation of serum miR-21-5p, miR-135-5p, and miR-155-5p expression levels.

Jing Zhang and Ji Guo contributed equally.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Colorectal cancer (CRC) is a prevalent malignant tumor caused by flora disequilibrium [1, 2], with the third highest incidence rate (10%) and the second highest mortality rate (9.4%) globally. It poses a serious threat to the lives and health of people around the world [3]. The primary treatment for patients with CRC is surgical resection of tumor lesions. However, perioperative procedures such as preoperative intestinal preparation [4], antibiotic prophylaxis [5, 6], and radical surgery [7, 8] can damage the intestinal barrier, resulting in intestinal flora disequilibrium. It is important to observe that postoperative intestinal flora dysbiosis is strongly associated with the prognosis and recurrence of CRC [9, 10]. In CRC, the perioperative administration of microecological enteral nutrition interventions, such as Bifidobacterium and Lactobacillus, is a safe and reliable approach for treating postoperative intestinal flora dysbiosis. These interventions play a role in deactivating oncogenic factors, regulating host immunity, controlling apoptosis and proliferation, and improving the integrity of the intestinal mucosa through multiple mechanisms [11, 12]. However, the specific mechanisms underlying these effects are not yet completely understood [13].

Recent research on the role of probiotics in CRC has gradually expanded from protein-coding genes to non-coding RNAs, such as microRNAs (miRNAs), long intergenic non-coding RNAs, and circular RNAs [1, 2]. miRNAs usually bind to the 3′-untranslated area (3′-UTR) of a specific target mRNA. This binding inhibits messenger RNA (mRNA) translation through degradation of the mRNA and further contributes to the development of cancer. In cancer development, dysregulation of transcription and aberrant expression of miRNAs can have oncogenic or carcinogenic effects, thereby regulating the progression of tumors. Primarily, these effects involve mechanisms such as regulating cell proliferation, inhibiting cell death, controlling tumor invasion and metastasis, and inducing angiogenesis [14].

Recent years have seen several strategies developed for inhibiting oncomiRNA in vivo [15]. Hence, in this study, we focused on overexpressed miRNAs that can regulate the intestinal flora in the perioperative period of CRC. The target miRNA adopted in this study was initially selected by analyzing the miRNA database and summarizing the literature. First, we investigated the ranking order of miRNAs associated with intestinal differentiation, structure, and barrier function [16]. Using the miRCancer database (http://mircancer.ecu.edu), we determined that the aforementioned miRNAs were abnormally expressed in CRC. MiR-21-5p, miR-135-5p, and miR-155-5p all regulate the inflammatory process of digestive diseases through the immune system; this is consistent with previous research [17‐19]. In addition, alterations in the expression levels of miR-21-5p [20, 21], miR-135-5p [22], and miR-155-5p [23] in serum can be utilized for the early diagnosis of CRC, prediction of treatment outcomes, and prognosis. It has also been shown that the dysregulation of these three miRNAs may lead to drug resistance, and restoring the dysregulated miRNAs could effectively overcome this resistance. In CRC patients with high miR-21-5p [24], miR-135-5p [25], and miR-155-5p [15] expression, overall survival and disease-free survival rates were significantly worse than in patients with low miR-21-5p, miR-135-5p, and miR-155-5p expression. Moreover, Liang et al. found that the co-delivery of functional miR-21 and anticancer drugs by exosomes reverses colorectal cancer resistance, thereby improving the efficacy of cancer therapy [26]. A novel strategy to sensitize CRC to chemotherapy may involve the use of miR-135 antisense nucleotides [15]. Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles is a promising treatment for colorectal cancer [27]. Therefore, in this study, we evaluated the dynamic changes in the expression levels of a group of circulating miRNAs, including miR-21-5p, miR-135-5p, and miR-155-5p, before and after the perioperative period of CRC.

Bifidobacterium triplex viable capsule is a co-probiotic that has been extensively used in the diagnosis and treatment of inflammatory diseases of the intestinal tract and CRC. In this study, Bifidobacterium triplex viable capsules were administered as a perioperative probiotic to patients with CRC. Our objective was to investigate the changes in the expression levels of serum circulating miR-21-5p, miR-135-5p, and miR-155-5p in patients with CRC who received Bifidobacterium triplex viable capsules perioperatively. This research will provide a foundation for investigating the mechanism of action of Bifidobacterium triplex viable capsules in promoting perioperative recovery in patients with colorectal cancer.

Materials and methods

Patient recruitment

A total of 60 primary patients with CRC admitted to the Department of General Surgery at Shanxi Bethune Hospital between June 2020 and December 2020 were selected with a 3-year follow-up. Using the randomization method, they were randomly divided into two groups: 20 cases in the control group and 40 cases in the experimental group. Blood samples were collected from the Department of General Surgery at Shanxi Bethune Hospital for this study. The Ethics Committee of Shanxi Bethune Hospital (YXLL-2019–062) reviewed and approved the study protocol, and all patients provided informed consent by signing a consent form.

Patients were included based on the following criteria: 1. age between 45 and 85 years old; 2. an imaging examination, intraoperative exploration, and gastrointestinal endoscopy confirmed that the tumor was solitary and had no metastasis; 3. standard radical surgeries for CRC were conducted; 4. pathological analysis of postoperative specimens confirmed the presence of malignant tumors; 5. TNM stages were classified as stages I–III. Patients with the following conditions were excluded: 1. preoperative complications such as intestinal perforation or obstruction; 2. detection of distant metastases through preoperative imaging or intraoperative examination; 3. previous history of oncological surgical treatment; 4. history of colorectal surgery; 5. recent use of antibiotics and probiotics; 6. history of infectious diseases; 7. history of diabetes mellitus, hypertension, or coronary heart disease.

Perioperative treatment and probiotics

Bifidobacterium triple viable capsules, marketed as Bifico, were the probiotics utilized in the study. The capsule contains Bifidobacterium longum, Lactobacillus, and Enterococcus. Each capsule contains 210 mg of pharmaceutical powder and a minimum of 1.0*10^{^7} CFU of live bacteria. The placebo capsules were indistinguishable from the Bifidobacterium triplex viable capsules in terms of taste and texture. The only difference was that the placebo capsules lacked any live microorganisms. Both samples were prepared in capsule form, placed in aluminum foil pouches, and stored at room temperature. Shanghai Sine Pharmaceutical Laboratories Co., Ltd. manufactured the probiotics and placebos used in the study.

All patients were given semi-liquid food 3 days prior to surgery, full liquid food 1 day prior to surgery, oral Folium Sennae 3 days prior to surgery to cleanse the intestinal tract, no food or liquids for 12 h prior to surgery, and compound polyethylene glycol electrolytes to prepare the intestinal tract until the stools were watery.

The same group of physicians performed the surgery and anesthesia. The probiotic, Bifidobacterium triplex viable capsule, was administered orally for 3 days prior to surgery to the experimental group, with four capsules per dose, taken twice daily. The capsules were consumed with a sip of water after surgery and continued for 7 days. The placebo was administered orally to the control group, and all other procedures were identical to the experimental group. Before and after the skin incision, prophylactic antibiotics and nutritional support were routinely administered to prevent infection.

Collection of serum samples

Fasting blood was collected from patients 3 days before and 7 days after surgery. Approximately 4 mL of whole blood was drawn from the vein at the elbow and placed in a serum collection tube. The tube was then left at room temperature for 1 h before being centrifuged at 4 °C for 10 min at a low speed of 1200 g/min. After centrifugation, the upper layer of serum was transferred to 1.5 mL EP tubes at 1 mL per tube. To remove any remaining cellular debris from the previous low-speed centrifugation, the tubes were centrifuged at a high speed of 12,000g/min at 4 °C for 5 min. The supernatant was then pipetted and dispensed into new 1.5 mL EP tubes at 500 μL per tube. The top cap of each tube was sealed with a membrane and labeled according to the grouping. The tubes were then placed in a refrigerator with a temperature of − 80 °C for storage.

RNA extraction and miRNA expression detection

Total RNA was extracted using the Total RNA Extractor manufactured by Sangon Biotech (Shanghai). Using a spectrophotometer, the concentration and purity of the extracted RNA were detected. Reverse transcription was performed using the All-in-One™ miRNA qRT-PCR Detection System 2.0 manufactured by Gene Copoeia. RNA was reverse transcribed into complementary DNA (cDNA). The cDNA was used as a template for quantitative experiments on miRNAs in a PCR instrument using the PerfectStart® Green qPCR SuperMix from TransGen Biotech.

Statistical analysis

Using the 2^−ΔΔCt method, the experimental data were processed and analyzed. In this method, △Ct _preoperative = the mean ± standard deviation of (the Ct value of the target gene minus the Ct value of the internal reference). Similarly, △Ct _{postoperative} = the mean ± standard deviation of (the Ct value of the target gene minus the Ct value of the internal reference). Finally, △△Ct = the mean ± standard deviation of (the postoperative △Ct minus the preoperative △Ct).

SPSS 25.0 software was used for statistical analysis, and GraphPad Prism 8 was used to create graphs. The paired t test was used to compare the relative expression content of miRNAs in serum within the two groups. Using a t test for independent samples, the relative expression content of miRNAs between the two groups was compared. Using a chi-squared test or Fisher’s exact test, a comparison of the counting data was performed.

The follow-up period was defined as the time interval between the date of informed consent until death or last clinical contact (Dec, 2023). Disease-free survival (DFS) is defined as the time from randomization to tumor recurrence of primary cancer, new CRC, distant metastases, or death from any cause, whichever comes first. We compared patient survival using the Kaplan–Meier method and the log-rank test. The significance level of the test was set at 0.05, and a P value of ≤ 0.05 indicated that the differences observed were statistically significant.

Results

Comparison of general data of patients in the two groups

This investigation included a total of 60 patients with CRC, with 20 cases in the control group and 40 cases in the experimental group (Fig. 1). The average age of enrollment was 66 years old; 51.7% (31/60) of the participants were male, while 48.3% (29/60) were female. In terms of lesion location, 30% of the tumors were found in the ascending colon, 15% in the descending colon, 31.7% in the sigmoid colon, and 23.3% in the rectum. According to the TNM staging method, stage I and II CRCs accounted for approximately 56.7%, while stage III CRCs accounted for 43.3%.

There was no statistical difference (P > 0.05) between the two groups in terms of patient gender (P = 0.465), age (P = 0.566), lesion location (P = 0.194), and TNM staging (P = 0.442). The specific conditions of the enrolled patients are presented in Table 1.

Table 1

Basic information of enrolled patients

Group	Control group (n = 20)	Experimental group (n = 40)	X² value	P value
Gender
Male	9(45.0%)	22(55.0%)	0.534	0.465
Female	11(55.0%)	18(45.0%)	0.534	0.465
Age
≥ 60	8(40.0%)	13(32.5%)	0.330	0.566
< 60	12(60.0%)	27(67.5%)	0.330	0.566
Location of lesion
Ascending colon	4(20.0%)	14(35.0%)	4.715	0.194
Descending colon	3(15.0%)	6(15.0%)
Sigmoid colon	5(25.0%)	14(35.0%)
Rectum	8(40.0%)	6(15.0%)
TNM
I	1(5.0%)	5(12.5%)	1.786	0.442
II	8(40.0%)	20(50.0%)
III	11(55.0%)	15(37.5%)

Comparison of postoperative complication occurrence between the two groups

Among the experimental group patients, there was one case of postoperative urinary system infection, resulting in a complication rate of 2.5% (1/40). In the control group, there was one case of postoperative pulmonary infection and one case of urinary system infection, resulting in a complication rate of 10.0% (2/20). The difference between the two groups was statistically significant (P < 0.05).

Differences in the relative expression content of miRNAs in serum between the two groups

First, we analyzed and compared the differences in the relative expression levels of miRNAs in the serum of patients between the two groups. In the control group, postoperative expression of miR-21-5p decreased compared to preoperative levels (t = − 5.977, P = 0.000). Similarly, miR-135-5p expression also decreased postoperatively compared to preoperative levels (t = − 5.522, P = 0.000). In addition, miR-155-5p expression decreased postoperatively compared to preoperative levels (t = − 2.201, P = 0.040). Figure 2 illustrates the specific changes in the differences between the preoperative and postoperative periods. All three miRNAs detected in this study showed a decrease in expression after surgery (P < 0.05). Among them, the significant difference in expression levels was larger for miR-21-5p and miR-135-5p (P < 0.001).

Compared to the preoperative period, the expression of miR-21-5p decreased significantly in the experimental group patients (t = − 11.361, P = 0.000). Similarly, the expression of miR-135-5p also decreased compared to the preoperative period (t = − 9.006, P = 0.000), as did the expression of miR-155-5p (t = − 3.377, P = 0.002). Figure 3 illustrates the specific changes in the difference between the preoperative and postoperative periods. Before and after the surgery, the three previously mentioned miRNAs exhibited the same trend of change in the experimental group as observed in the control group.

Differences in the relative expression levels of miRNAs in serum between groups

In addition, we compared and analyzed the differences in the relative expression levels of miRNAs in serum between the control group and the experimental group before and after the intervention of placebo or Bifidobacterium triplex viable capsules. Figure 4 demonstrates that there was no significant difference in the expression of miR-21-5p (P = 0.313), miR-135-5p (P = 0.744), and miR-155-5p (P = 0.974) between the two groups of patients before the intervention of placebo or Bifidobacterium triplex viable capsule (P > 0.05).

The expression of miR-21-5p (t = − 2.398, P = 0.020) and miR-135-5p (t = − 2.343, P = 0.023) decreased in the experimental group compared to the control group after the administration of probiotics (7 days postoperatively). However, there was no significant change in the relative expression of miR-155-5p (t = 0.084, P = 0.933). These findings suggest that probiotics have a certain impact on the expression of miRNAs, as depicted in Fig. 5.

Relationship between the levels of miRNAs after surgery and patients’ survival

Finally, we compared and analyzed the differences in the OS and DFS between the two groups. In the Kaplan–Meier survival curve analysis of all patients, 3-year OS (HR = 4.21; 95% CI 0.37–47.48; log-rank P = 0.20) or 3-year DFS (HR = 1.57; 95% CI 0.32–7.66; log-rank P = 0.55) rates of the experimental patients with lower miR-21-5p, miR-135-5p, and miR-155-5p expression were not significantly longer than these patients in the control group (Fig. 6).

Discussion

In studies investigating the relationship between CRC and intestinal flora, researchers discovered that the diversity and abundance of bacteria in the intestinal mucosa and feces of patients with CRC are significantly altered. Specifically, the levels of beneficial bacteria such as Bifidobacterium and Faecalibacterium tend to decrease, while the levels of harmful bacteria such as E. faecalis and Fusobacterium nucleatum tend to increase [11]. This imbalance in intestinal bacterial composition results in varying degrees of intestinal flora dysbiosis, which in turn increases permeability of the intestinal mucosa and levels of inflammatory factors. It is believed that these changes play a crucial role in the development and progression of CRC [28]. Probiotic supplementation can effectively regulate the composition of the intestinal flora and influence the development and treatment of CRC [12, 29, 30]. However, its specific mechanism is still unclear.

In this investigation, we conducted a study on patients with CRC who received perioperative Bifidobacterium triplex viable capsules. We found that the incidence of postoperative complications was lower in the experimental group than in the control group (2.5% vs. 10.0%). Using the expression of circulating miRNAs as the primary observational index, the effect of using Bifidobacterium triplex viable capsules on the expression of serum miRNAs in patients with CRC was investigated. The results indicated that both experimental and control group patients showed a decrease in the expression content of miR-21-5p, miR-135-5p, and miR-155-5p 7 days after surgery (P < 0.05). Among them, miR-21-5p and miR-135-5p were significantly different (P < 0.001), indicating that radical surgery to remove the tumor load can affect the expression of oncogenic miRNA content in serum. This result is consistent with previous research findings. Both Toiyam et al. [20] and Li et al. [21] analyzed serum miR-21-5p levels comparatively between patients with CRC and healthy populations, and the results showed that serum miR-21-5p levels were higher in patients with CRC than in healthy populations preoperatively and that miR-21-5p levels were significantly lower in the postoperative period compared to the preoperative period (P < 0.001). The decrease in serum miR-21-5p (P = 0.020) and miR-135-5p (P = 0.023) expression after the intervention of Bifidobacterium triplex capsules was obvious, suggesting that Bifidobacterium triplex viable capsules could reduce the expression of oncogenic miRNAs in the serum; meanwhile, the trend of the above-mentioned miRNA expression content suggests that the use of Bifidobacterium triplex viable capsules may be beneficial to the treatment of tumors. Heydari et al. [31] also discovered that Lactobacillus and Bifidobacterium enhanced the therapeutic efficacy of colon cancer treatment in a mouse model of colon cancer by increasing the expression of oncogenic miRNAs and their target genes and decreasing the expression of oncogenic genes. Regarding its specific mechanism, miR-21-5p acts as a pro-oncogenic factor. MiR-21-5p may be activated by the phosphatidylinositol-3-kinase (PI3K), signal transducer and activator of transcription 3 (STAT3), and programmed cell death factor 4/tumor necrosis factor-α (PDCD4/TNF-α) signaling pathways, which affect inflammatory processes and tumor progression in CRC [32]. Meanwhile, they play a role in regulating the inflammatory process of CRC, which may synergize with intestinal flora dysbiosis to regulate downstream inflammatory factors (e.g., interleukin-6, TNF-α) and control the inflammatory process of tumors. In addition, probiotics can alter the structure of the intestinal flora and increase the population of beneficial bacteria. This can help combat the persistent inflammatory response caused by dysbiosis and potentially have a therapeutic effect on CRC by regulating tumor-associated pathways [12]. miR-135-5p is a cancer-promoting factor, and the high expression of miR-135-5p in patients with CRC is associated with adenomatous polyposis coli (APC) gene deletion, phosphatase, and tensin homolog (PTEN)/PI3K pathway dysregulation, and altered expression levels of circulating RNA circNOL10 [33, 34]. In the study by Han et al., interleukin 1 upregulated miR-135b to promote inflammation-associated gastric carcinogenesis in mice, suggesting that miR-135-5p promotes the inflammatory process in digestive diseases. In contrast, miR-155-5p promotes the progression of CRC by targeting the negative regulator suppressor of cytokine signaling 1 (SOCS1) and SH2 domain-containing inositol 5-phosphatase 1 (SHIP1) to enhance Toll-like receptor 4 polypeptide (TLR4) signaling; TLR4 activation induces miR-155-5p expression through transcriptional and post-transcriptional mechanisms [35]. The expression level of miR-155-5p in the experimental group decreased significantly after surgery compared with that in the control group before and after surgery (P = 0.002). However, compared with miR-21-5p and miR-135-5p, there was no statistical difference before and after surgery in miR-155-5p (P = 0.933), which may be due to the deviation of the limited sample size in this study. This may be one of the mechanisms by which the intestinal flora improves the expression level of miRNAs; however, further research is required to confirm this hypothesis.

Traditionally, the TNM stage has been the main classification system guiding prognosis. However, in the recent decade, greater emphasis on molecular biomarkers such as microsatellite instability (MSI) [36], kirsten rat sarcoma virus (KRAS) [36], circulating tumor DNA (ctDNA) [37], and miRNAs [38], improves the accuracy of prognostication. In this present study, there was no significant statistical difference of the 3-year OS (HR = 4.21; 95% CI 0.37–47.48; log-rank P = 0.20) or 3-year DFS (HR = 1.57; 95% CI 0.32–7.66; log-rank P = 0.55) in two groups. However, the miR-21-5p [24], miR-135-5p [25], and miR-155-5p [15] expression levels in CRC patients were independent prognostic factors for OS and DFS. Possibly, this is due to our short follow-up time or the stage I–III in the study population or the fact that our study only included perioperative oral probiotics.

The primary limitation of this investigation is the small sample size, and the results of the study must be confirmed by a larger sample size. To further investigate the mechanism of action of Bifidobacterium triplex viable capsules in promoting the perioperative recovery of patients with CRC, we established an oral placebo group as the control group, but healthy people were not included. This was done to exclude any potential effects on intestinal flora caused by the prophylactic use of antibiotics and bowel preparation that were clinically necessary. This may differ slightly from the real world. It is worth noting that in this study, only quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used, which is the gold standard tool to detect miRNAs, and the results of the study were preliminary, and in further studies, RNA sequencing will be used simultaneously to support our research, and all enrolled patients’ survival outcomes will be collected. Studying survival data from experimental and control groups and comparing whether there is a statistical difference, multivariate analysis was not used to confirm the association between the patients’ stratification, clinicopathologic data, and circulating miRNA expression, to test the hypothesis that Bifidobacterium triplex viable capsules might downregulate the expression level of oncomiRNA to enhance the CRC patients’ anti-cancer ability, providing a potential for anti-cancer treatment. In addition, the mechanism of targeted miRNAs affecting patients’ disease course and the correlation between the colonization of probiotics in patients and miRNA changes also need to be further analyzed.

In conclusion, the utilization of Bifidobacterium triplex viable capsules has the potential to enhance the postoperative recuperation of patients with CRC. This effect is achieved through significant modulation of the expression of miR-21-5p and miR-135-5p in the serum. These modifications in miRNA expression may be the reason why Bifidobacterium triplex viable capsules promote perioperative recovery in patients with colorectal cancer. This research seeks to contribute additional evidence supporting the optimal utilization of probiotic-based therapeutics in clinical settings.

Acknowledgements

We would like to acknowledge the hard and dedicated work of all the staff that implemented the intervention and evaluation components of the study.

Declarations

Ethics approval

This study was conducted with approval from the Ethics Committee of Shanxi Bethune Hospital (YXLL-2019–062).

This study was conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants.

Not applicable.

Competing interests

The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!

Jetzt informieren

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt testen ¹

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Jetzt testen ²

Tilg H, Adolph TE, Gerner RR, Moschen AR (2018) The intestinal microbiota in colorectal cancer. Cancer Cell 33(6):954–964. https://doi.org/10.1016/j.ccell.2018.03.004CrossRefPubMed

Wong SH, Yu J (2019) Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol 16(11):690–704. https://doi.org/10.1038/s41575-019-0209-8CrossRefPubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660CrossRefPubMed

Krezalek MA, Hyoju S, Zaborin A, Okafor E, Chandrasekar L, Bindokas V et al (2018) Can methicillin-resistant Staphylococcus aureus silently travel from the gut to the wound and cause postoperative infection? Modeling the “Trojan horse hypothesis.” Ann Surg 267(4):749–758. https://doi.org/10.1097/SLA.0000000000002173CrossRefPubMed

Yang J, Yu J (2018) The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get. Protein Cell 9(5):474–487. https://doi.org/10.1007/s13238-018-0543-6CrossRefPubMedPubMedCentral

Lavelle A, Hoffmann TW, Pham HP, Langella P, Guédon E, Sokol H (2019) Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. Microbiome 7(1):111. https://doi.org/10.1186/s40168-019-0725-3CrossRefPubMedPubMedCentral

Kong C, Gao R, Yan X, Huang L, He J, Li H et al (2019) Alterations in intestinal microbiota of colorectal cancer patients receiving radical surgery combined with adjuvant CapeOx therapy. Sci China Life Sci 62(9):1178–1193. https://doi.org/10.1007/s11427-018-9456-xCrossRefPubMed

Colov EP, Degett TH, Raskov H, Gögenur I (2020) The impact of the gut microbiota on prognosis after surgery for colorectal cancer - a systematic review and meta-analysis. APMIS 128(2):162–176. https://doi.org/10.1111/apm.13032CrossRefPubMed

Lauka L, Reitano E, Carra MC, Gaiani F, Gavriilidis P, Brunetti F et al (2019) Role of the intestinal microbiome in colorectal cancer surgery outcomes. World J Surg Oncol 17(1):204. https://doi.org/10.1186/s12957-019-1754-xCrossRefPubMedPubMedCentral

10.

Ouyang X, Li Q, Shi M, Niu D, Song W, Nian Q et al (2019) Probiotics for preventing postoperative infection in colorectal cancer patients: a systematic review and meta-analysis. Int J Colorectal Dis 34(3):459–469. https://doi.org/10.1007/s00384-018-3214-4CrossRefPubMed

11.

Eslami M, Yousefi B, Kokhaei P, Hemati M, Nejad ZR, Arabkari V et al (2019) Importance of probiotics in the prevention and treatment of colorectal cancer. J Cell Physiol 234(10):17127–17143. https://doi.org/10.1002/jcp.28473CrossRefPubMed

12.

Ding S, Hu C, Fang J, Liu G (2020) The protective role of probiotics against colorectal cancer. Oxid Med Cell Longev 2020:8884583. https://doi.org/10.1155/2020/8884583CrossRefPubMedPubMedCentral

13.

Zununi Vahed S, Barzegari A, Rahbar Saadat Y, Goreyshi A, Omidi Y (2017) Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways. Biomed Pharmacother 94:1094–1100. https://doi.org/10.1016/j.biopha.2017.08.033CrossRefPubMed

14.

Peng Y, Croce CM (2016) The role of microRNAs in human cancer. Signal Transduct Target Ther 1:15004. https://doi.org/10.1038/sigtrans.2015.4CrossRefPubMedPubMedCentral

15.

Ulivi P, Canale M, Passardi A, Marisi G, Valgiusti M, Frassineti GL, Calistri D, Amadori D, Scarpi E (2018) Circulating plasma levels of miR-20b, miR-29b and miR-155 as predictors of bevacizumab efficacy in patients with metastatic colorectal cancer. Int J Mol Sci 19(1):307. https://doi.org/10.3390/ijms19010307CrossRefPubMedPubMedCentral

16.

McKenna LB, Schug J, Vourekas A, McKenna JB, Bramswig NC, Friedman JR et al (2010) MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 139(5):1654–64. https://doi.org/10.1053/j.gastro.2010.07.040CrossRefPubMed

17.

Bi K, Zhang X, Chen W, Diao H (2020) MicroRNAs regulate intestinal immunity and gut microbiota for gastrointestinal health: a comprehensive review. Genes (Basel) 11(9):1075. https://doi.org/10.3390/genes11091075CrossRefPubMed

18.

Teodori L, Petrignani I, Giuliani A, Prattichizzo F, Gurău F, Matacchione G et al (2019) Inflamm-aging microRNAs may integrate signals from food and gut microbiota by modulating common signalling pathways. Mech Ageing Dev 182:111127. https://doi.org/10.1016/j.mad.2019.111127CrossRefPubMed

19.

Han TS, Voon DC, Oshima H, Nakayama M, Echizen K, Sakai E et al (2019) Interleukin 1 Up-regulates microRNA 135b to promote inflammation-associated gastric carcinogenesis in mice. Gastroenterology 156(4):1140-1155.e4. https://doi.org/10.1053/j.gastro.2018.11.059CrossRefPubMed

20.

Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y et al (2013) Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst 105(12):849–859. https://doi.org/10.1093/jnci/djt101CrossRefPubMedPubMedCentral

21.

Li G, Wang Q, Li Z, Shen Y (2020) Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer. Rev Esp Enferm Dig 112(11):832–837. https://doi.org/10.17235/reed.2020.6801/2019CrossRefPubMed

22.

Li L, Wang A, Cai M, Tong M, Chen F, Huang L (2020) Identification of stool miR-135b-5p as a non-invasive diaognostic biomarker in later tumor stage of colorectal cancer. Life Sci 260:118417. https://doi.org/10.1016/j.lfs.2020.118417CrossRefPubMed

23.

Bocchetti M, Ferraro MG, Ricciardiello F, Ottaiano A, Luce A, Cossu AM et al (2021) The role of microRNAs in development of colitis-associated colorectal cancer. Int J Mol Sci 22(8):3967. https://doi.org/10.3390/ijms22083967CrossRefPubMedPubMedCentral

24.

Tsukamoto M, Iinuma H, Yagi T, Matsuda K, Hashiguchi Y (2017) Circulating exosomal microRNA-21 as a biomarker in each tumor stage of colorectal cancer. Oncology 92(6):360–370. https://doi.org/10.1159/000463387CrossRefPubMed

25.

Babaei-Jadidi R, Kashfi H, Alelwani W, Karimi Bakhtiari A, Kattan SW, Mansouri OA, Mukherjee A, Lobo DN, Nateri AS (2022) Anti-miR-135/SPOCK1 axis antagonizes the influence of metabolism on drug response in intestinal/colon tumour organoids. Oncogenesis 11(1):4. https://doi.org/10.1038/s41389-021-00376-1CrossRefPubMedPubMedCentral

26.

Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si K et al (2020) Engineered exosomes for targeted co-delivery of miR-21 inhibitor and chemotherapeutics to reverse drug resistance in colon cancer. J Nanobiotechnology 18(1):10. https://doi.org/10.1186/s12951-019-0563-2CrossRefPubMedPubMedCentral

27.

Li Y, Duo Y, Bi J, Zeng X, Mei L, Bao S et al (2018) Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy. Int J Nanomedicine 13:1241–1256. https://doi.org/10.2147/IJN.S158290CrossRefPubMedPubMedCentral

28.

Percario R, Panaccio P, di Mola FF, Grottola T, Di Sebastiano P (2021) The complex network between inflammation and colorectal cancer: a systematic review of the literature. Cancers (Basel) 13(24):6237. https://doi.org/10.3390/cancers13246237CrossRefPubMed

29.

Kaźmierczak-Siedlecka K, Roviello G, Catalano M, Polom K (2021) Gut microbiota modulation in the context of immune-related aspects of Lactobacillus spp. and Bifidobacterium spp. in gastrointestinal cancers. Nutrients 13(8):2674. https://doi.org/10.3390/nu13082674CrossRefPubMedPubMedCentral

30.

Wei H, Chen L, Lian G, Yang J, Li F, Zou Y et al (2018) Antitumor mechanisms of bifidobacteria. Oncol Lett 16(1):3–8. https://doi.org/10.3892/ol.2018.8692CrossRefPubMedPubMedCentral

31.

Heydari Z, Rahaie M, Alizadeh AM, Agah S, Khalighfard S, Bahmani S (2019) Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the expression of microRNAs 135b, 26b, 18a and 155, and Their Involving Genes in Mice Colon Cancer. Probiotics Antimicrob Proteins 11(4):1155–1162. https://doi.org/10.1007/s12602-018-9478-8CrossRefPubMed

32.

Lai CY, Yeh KY, Liu BF, Chang TM, Chang CH, Liao YF et al (2021) MicroRNA-21 plays multiple oncometabolic roles in colitis-associated carcinoma and colorectal cancer via the PI3K/AKT, STAT3, and PDCD4/TNF-α signaling pathways in zebrafish. Cancers (Basel) 13(21):5565. https://doi.org/10.3390/cancers13215565CrossRefPubMed

33.

Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V et al (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25(4):469–483. https://doi.org/10.1016/j.ccr.2014.03.006CrossRefPubMedPubMedCentral

34.

Zhang Y, Zhang Z, Yi Y, Wang Y, Fu J (2020) CircNOL10 acts as a sponge of miR-135a/b-5p in suppressing colorectal cancer progression via regulating KLF9. Onco Targets Ther 13:5165–5176. https://doi.org/10.2147/OTT.S242001CrossRefPubMedPubMedCentral

35.

Guo J, Liao M, Wang J (2021) TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155. Cell Commun Signal 19(1):90. https://doi.org/10.1186/s12964-021-00771-6CrossRefPubMedPubMedCentral

36.

Chen K, Collins G, Wang H, Toh JWT (2021) Pathological features and prognostication in colorectal cancer. Curr Oncol 28(6):5356–5383. https://doi.org/10.3390/curroncol28060447CrossRefPubMedPubMedCentral

37.

Zhou H, Zhu L, Song J, Wang G, Li P, Li W, Luo P, Sun X, Wu J, Liu Y, Zhu S, Zhang Y (2022) Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer 21(1):86. https://doi.org/10.1186/s12943-022-01556-2CrossRefPubMedPubMedCentral

38.

Chen B, Xia Z, Deng YN, Yang Y, Zhang P, Zhu H, Xu N, Liang S (2019) Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol 9(1):180212. https://doi.org/10.1098/rsob.180212CrossRefPubMedPubMedCentral

Titel: Analysis of the differential expression of serum miR-21-5p, miR-135-5p, and miR-155-5p by Bifidobacterium triplex viable capsules during the perioperative stage of colorectal cancer
verfasst von: Jing Zhang
Ji Guo
Ruochong He
Ji Li
Bingyi Du
Yi Zhang
Rongliang He
Haixia Cheng
Publikationsdatum: 01.12.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: International Journal of Colorectal Disease / Ausgabe 1/2024
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-024-04617-8

Neu im Fachgebiet Chirurgie

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Publisher's Note

Introduction

Materials and methods

Patient recruitment

Perioperative treatment and probiotics

Collection of serum samples

RNA extraction and miRNA expression detection

Statistical analysis

Results

Comparison of general data of patients in the two groups

Comparison of postoperative complication occurrence between the two groups

Differences in the relative expression content of miRNAs in serum between the two groups

Differences in the relative expression levels of miRNAs in serum between groups

Relationship between the levels of miRNAs after surgery and patients’ survival

Discussion

Acknowledgements

Declarations

Ethics approval

Consent to participate

Consent for publication

Competing interests

Publisher's Note

Unsere Produktempfehlungen

Die Chirurgie

e.Med Interdisziplinär

e.Med Innere Medizin

Weitere Artikel der Ausgabe 1/2024

Prognostic value of depression and anxiety on colorectal cancer-related mortality: a systematic review and meta-analysis based on univariate and multivariate data

Bowel preparation for elective colorectal resection: multi-treatment machine learning analysis on 6241 cases from a prospective Italian cohort

Correction to: Evolution of surgical approach to rectal cancer resection: A multinational registry assessment

Reliability and validity of the Turkish version of the New Cleveland Clinic Colorectal Cancer Quality of Life Questionnaire

The impact of aspirin use on outcomes in patients with inflammatory bowel disease: Insights from a national database

Efficacy of electroacupuncture therapy in patients with functional anorectal pain: study protocol for a multicenter randomized controlled trial

Update Chirurgie